Table 2 Favorability ratings of immunomodulatory therapies
From: Corticosteroid-sparing therapy: practice patterns among uveitis specialists
MTX | MMF | AZA | CSA | CTX | INF | ADA | |
|---|---|---|---|---|---|---|---|
Favorablea | |||||||
Anterior | 28 (62%) | 24 (53%) | 13 (29%) | 9 (20%) | 21 (47%) | 37 (82%) | 33 (73%) |
Intermediate | 20 (44%) | 27 (60%) | 14 (31%) | 17 (38%) | 24 (53%) | 31 (69%) | 26 (58%) |
Posterior/panuveitis | 10 (22%) | 24 (53%) | 15 (33%) | 20 (44%) | 32 (71%) | 32 (71%) | 25 (56%) |
No opinion | |||||||
Anterior | 0 (0%) | 7 (16%) | 19 (42%) | 16 (36%) | 20 (44%) | 5 (11%) | 10 (22%) |
Intermediate | 1 (2%) | 4 (9%) | 13 (29%) | 11 (24%) | 17 (38%) | 7 (16%) | 12 (27%) |
Posterior/panuveitis | 1 (2%) | 2 (4%) | 11 (24%) | 7 (16%) | 9 (20%) | 7 (16%) | 16 (36%) |